SMAD4 and cancer: For example, TGFβ–BMP signalling was mostly inactivated by co-SMAD SMAD4 mutations in MSS cancers, but by one or more indel receptor mutations (TGFBR2, ACVR2A, BMPR2 and ACVR1B) in MSI cancers.